LAST CHANCE to Register: MSD 2023 Insurance Payer Workshop

DON'T WAIT... Registration is closing for the 2023 Insurance Payer Workshop. Get all of the latest updates from the top payers. This session will be held virtually on Thursday, January 26, 2023, from 8:00 am – 12:30 pm. Presenters include Aetna, AmeriHealth Caritas, CMS, Cigna, Highmark, United Healthcare, and Delaware First Health. To register visit https://reg.planetreg.com/2023INSOWNERWORKSHOP.

New MCO Delaware First Health Shares Info for DE Practices

As you may be aware, Effective January 1, 2023, the Delaware Department of Health and Social Services (DHSS) has contracted with “Delaware First Health” as the newest Delaware Medicaid Managed Care Organization (MCO), joining Highmark Health Options and AmeriHealth Caritas DE. In order to ensure a smooth transition for both practices and patients and that care of Medicaid members continues uninterrupted, Delaware First Health is sharing important information to accomplish this goal. Please follow the enclosed links for additional information, based on your current status as either a participating or non-participating practice with Delaware First Health. Delaware First Health Participating Practices: https://tinyurl.com/mwyhw665. If you have any additional questions, visit DelawareFirstHealth.com or call (877) 236-1341 for more information. Non-Participating Practices: https://tinyurl.com/2p92wtad.

DATA-Waiver Registration No Longer Required New Training Requirements to be Introduced for Prescribers

The U.S. Drug Enforcement Administration (DEA) announced (https://tinyurl.com/4m3um3nv) a change to the DEA registration requirement, which was sent to DEA registrants. With the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the “DATA-Waiver Program.” The elimination of the X-Waiver will increase access to buprenorphine for those in need. All physicians and health care practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law.

All DEA registrants should be aware of the following: 1) A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder. 2) Going forward, all prescriptions for buprenorphine need only be recorded in a DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription. 3) There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine. 4) The Act does not impact existing state laws or regulations that may be applicable. (Refer to Delaware Policy and Procedure https://tinyurl.com/y4a7t9dv).

Separately, the Act also introduced new training requirements for all prescribers. These requirements will not go into effect until June 21, 2023. The DEA and Substance Abuse and Mental Health Services Administration (SAMHSA) are actively working to provide further guidance and DEA will follow up with additional information on these requirements shortly. Importantly, these new requirements do not impact the changes related to elimination of the DATA-Waiver Program described above.

CDC Investigates Safety Risk of COVID Bivalent Booster

The Centers for Disease Control and Prevention's (CDC) Vaccine Safety Datalink (VSD), a near real-time surveillance system, met the statistical criteria to prompt additional investigation into whether there was an increased risk for ischemic stroke in people ages 65 and older who received the Pfizer-BioNTech COVID-19 Vaccine, Bivalent in the 21 days following vaccination compared with days 22-42 following vaccination. This preliminary signal has not been identified with the Moderna COVID-19 Vaccine, Bivalent. In a statement released last Friday, the totality of the data currently suggests that it is very unlikely that the signal in the VSD represents a true clinical risk. The CDC and the US Food and Drug Administration (FDA) will continue to evaluate the data from the safety monitoring systems and other vaccine safety systems. No change in vaccination practice is recommended. For more information visit https://tinyurl.com/593ea5jd.

AHRQ Safety Program for Telemedicine

Is your practice interested in improving the cancer diagnostic process for your patients who receive some or all of their care via telemedicine? The Agency for Healthcare Research and Quality (AHRQ) is recruiting practices for a free 18-month program to improve diagnostic verification, timeliness, and communication with patients. Practices will receive training and one-on-one expert coaching to implement sustainable improvements to effectively close the loop at critical points in the cancer diagnostic process. Learn more and sign up for an informational webinar on the program website https://tinyurl.com/4naxavny.